Eli Lilly's dual-drug obesity treatment demonstrates stronger weight reduction in Phase 2

Successful Phase 3 data and regulatory approval would likely establish Lilly's combo regimen as a meaningful competitor in the obesity market, potentially expanding the addressable patient population and supporting premium pricing if efficacy or tolerability advantages over existing GLP-1 therapies materialize.

If Phase 3 trials show modest or comparable efficacy to existing tirzepatide monotherapy without clear differentiation, the combo regimen could face adoption headwinds and market indifference, leaving Lilly's obesity franchise largely dependent on tirzepatide's existing competitive position.

Safety signals or efficacy shortfalls in Phase 3 could trigger regulatory delays or label restrictions, creating downside pressure on Lilly's obesity pipeline valuation and potentially benefiting competitors with established, well-tolerated single-agent therapies.